Trial Profile
Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Maraviroc (Primary) ; Antiretrovirals; Ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms GUSTA
- 27 Oct 2017 Results of substudy assessing immune activation/inflammation and microbial translocation presented at the 16th European AIDS Conference
- 05 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 03 Feb 2015 Planned End Date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.